Genomic Testing

Biomarker Testing for Your Cancer

Helomics offers a group of clinically relevant, cancer-related biomarker tests that determine how the biomarkers in your body are likely to respond to various types of chemotherapy and/or the course your disease is likely to take. Helomics believes that only the most well-validated biomarker tests should be used to determine treatment decisions, so biomarkers included in our portfolio are supported by current research and key opinion leaders. Many physicians utilize these biomarker expression results to help them better understand the unique characteristics of your particular cancer. It can help them choose between multiple, equivalent therapies, to make decisions on how aggressively to treat your cancer, or to suggest certain clinical trials for you, if you should qualify. The tumor types most frequently tested through Helomics panels are gynecologic cancers, lung cancer, breast cancer, colon cancer, and pancreatic cancer, but these tests are available for all solid tumor types.

Getting the Most Information about Your Cancer

BioSpeciFx® results can be used along with ChemoFx® treatment selection marker results to provide your physician with a Comprehensive Tumor Profile. Comprehensive Tumor Profiling is a unique approach that may allow your physician to more completely define a patient’s tumor. If your physician is considering chemotherapy and you are having or have already had your tumor removed, talk with your physician about these tests. All our testing is done in our CLIA Certified laboratory in Pittsburgh, PA.

Utilizing Biomarker Expression Results

Helomics biomarker results are presented in a clear, easy to understand format, including summaries of the clinical relevance of each test. Each patient report is generally delivered within 10-14 days of receiving the sample with all required paperwork, including signed test order form.

  • Clinically Relevant: Only markers relevant to your patient’s cancer type are included

  • Well validated: All markers have strong clinical evidence supporting their use: many are included in guidelines

  • Literature references provided, demonstrating link between marker and therapy

  • Results can be used in both the primary and recurrent settings